TW202328178A - 抗Ａβ初原纖維抗體的皮下配製物及其使用方法 - Google Patents

抗Ａβ初原纖維抗體的皮下配製物及其使用方法 Download PDF

Info

Publication number
TW202328178A
TW202328178A TW111132756A TW111132756A TW202328178A TW 202328178 A TW202328178 A TW 202328178A TW 111132756 A TW111132756 A TW 111132756A TW 111132756 A TW111132756 A TW 111132756A TW 202328178 A TW202328178 A TW 202328178A
Authority
TW
Taiwan
Prior art keywords
subject
pharmaceutical composition
seq
dose
week
Prior art date
Application number
TW111132756A
Other languages
English (en)
Chinese (zh)
Inventor
小山彰比古
查德 史旺森
道夫 金清
米雪兒 愛里沙瑞
琳恩 卡莫
珍 卡普洛
大衛 維貝爾
薩布哈 達哈達
帕拉宜 薩迪夫
拉里薩 瑞德曼
伊瑄妮 蘭德瑞
早戶誠一
羅伯特 戈登
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202328178A publication Critical patent/TW202328178A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111132756A 2021-08-30 2022-08-30 抗Ａβ初原纖維抗體的皮下配製物及其使用方法 TW202328178A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163260730P 2021-08-30 2021-08-30
US63/260,730 2021-08-30
US202263306050P 2022-02-02 2022-02-02
US63/306,050 2022-02-02
US202263269389P 2022-03-15 2022-03-15
US63/269,389 2022-03-15
US202263269463P 2022-03-16 2022-03-16
US63/269,463 2022-03-16
US202263364619P 2022-05-12 2022-05-12
US63/364,619 2022-05-12

Publications (1)

Publication Number Publication Date
TW202328178A true TW202328178A (zh) 2023-07-16

Family

ID=83438517

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132756A TW202328178A (zh) 2021-08-30 2022-08-30 抗Ａβ初原纖維抗體的皮下配製物及其使用方法

Country Status (9)

Country Link
US (1) US20240352109A1 (https=)
EP (1) EP4395821A1 (https=)
JP (1) JP2024532438A (https=)
KR (1) KR20240053620A (https=)
AU (1) AU2022338055A1 (https=)
CA (1) CA3230148A1 (https=)
MX (1) MX2024002567A (https=)
TW (1) TW202328178A (https=)
WO (1) WO2023034230A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030769A1 (zh) * 2023-08-10 2025-02-13 浙江格物致知生物科技有限公司 一种辅助诊断阿尔茨海默病的联检试剂盒及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260022396A (ko) * 2023-06-09 2026-02-19 에자이 알앤드디 매니지먼트 가부시키가이샤 항-Aβ 프로토피브릴 항체를 사용한 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
BR112019008359A2 (pt) * 2016-10-27 2019-10-01 Eisai R&D Man Co Ltd método para tratamento da doença de alzheimer, e, composição farmacêutica.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030769A1 (zh) * 2023-08-10 2025-02-13 浙江格物致知生物科技有限公司 一种辅助诊断阿尔茨海默病的联检试剂盒及应用

Also Published As

Publication number Publication date
US20240352109A1 (en) 2024-10-24
AU2022338055A1 (en) 2024-02-29
EP4395821A1 (en) 2024-07-10
MX2024002567A (es) 2024-03-20
JP2024532438A (ja) 2024-09-05
WO2023034230A1 (en) 2023-03-09
KR20240053620A (ko) 2024-04-24
CA3230148A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
TW202019471A (zh) 阿茲海默症之治療及預防方法
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
TW202328178A (zh) 抗Ａβ初原纖維抗體的皮下配製物及其使用方法
JP2024509960A (ja) 抗アミロイドベータ抗体及びその使用
TW202334201A (zh) 抗Ｔａｕ抗體之組成物、劑型及方法
TW202339794A (zh) 使用ｐ—ｔａｕ１８１水平之治療方法
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2020500165A (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ−セクレターゼｂａｃｅ１阻害剤を含む組成物
TW202430554A (zh) 使用ｔａｕ ＰＥＴ水平之治療方法
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
AU2015254661A9 (en) Treatment and prevention of Alzheimer's Disease (AD)
AU2015254663B2 (en) Treatment and prevention of Alzheimer's Disease (AD)
TW202313111A (zh) 治療阿茲海默症之方法
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116059340A (zh) 用于治疗复发形式的多发性硬化的方法